In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice
© Campion et al.; licensee BioMed Central Ltd. 2013
Received: 10 October 2012
Accepted: 30 January 2013
Published: 1 February 2013
Skip to main content
© Campion et al.; licensee BioMed Central Ltd. 2013
Received: 10 October 2012
Accepted: 30 January 2013
Published: 1 February 2013
Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo.
Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model.
More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 105 cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen.
This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.
As a result of their highly potent biological activities, lantibiotics have the potential to be employed as novel antimicrobials to combat medically significant bacteria and their multi-drug resistant forms [11–13]. Currently, a number of lantibiotics are under investigation for clinical use. NVB302, a semi-synthetic derivative of actagardine, is in stage I clinical trials with a view to treat infections caused by the hospital-acquired bacteria Clostridium difficile. Similarly, microbisporicin (under the commercial name NAI-107), which targets several multi-drug resistant (MDR) bacteria, is in late pre-clinical trials . In models of experimental infection involving mice and rats, the efficacy of microbisporicin in vivo was found to be comparable or superior to reference compounds (vancomycin and linezolid) in acute lethal infections induced with several MDR microbes, including methicillin resistant Staphylococcus aureus (MRSA), penicillin-intermediate Streptococcus pneumonia and vancomycin resistant enterococci (VRE) . Another lantibiotic, mutacin 1140 (produced by Streptococcus mutans) is also undergoing pre-clinical trials . Furthermore, a study involving the two peptide lantibiotic, lacticin 3147, has recently demonstrated its ability to prevent systemic spread of S. aureus in a murine infection model .
Nisin also displays potent in vitro activity against multi-drug resistant pathogens such as MRSA, vancomycin-intermediate and -heterogeneous S. aureus (VISA and hVISA, respectively) and VRE, [19–21] while natural variants such as nisin F also show potential in this regard . Notably, several studies have also demonstrated the in vivo efficacy of nisin A, [23–25] nisin Z, [26, 27] and Nisin F [28, 29]. Indeed, nisin F was recently shown to successfully treat respiratory disease caused by S. aureus K in immunocompromised Wistar rats . These animals were infected intranasally with 4 × 105 S. aureus cells prior to treatment with nisin F, also via the nasal route. Furthermore, nisin F was found to control the growth of S. aureus for up to 15 minutes in mice when injected into the peritoneal cavity . Animals were dosed with 1 × 108 S. aureus cells intraperitoneally and subsequently treated with nisin F, also via the intraperitoneal route. In a subsequent study, Nisin F-loaded brushite cement was shown to prevent the growth of S. aureus Xen 36 . The brushite cement was subcutaneously implanted into mice and infected with 1 × 103 S. aureus cells. Release of nisin F from the bone cement prevented S. aureus infection for 7 days.
Despite the potency of nisin and its natural variants, the gene encoded nature of these antimicrobials facilitates bioengineering thereof with a view to enhancing potency . Indeed, bioengineering of the hinge region of nisin A has been particularly successful in generating variants with enhanced potency against Gram-positive pathogens [32, 33]. One particular derivative, M21V (also known as nisin V), exhibits an in vitro activity against L. monocytogenes (the causative agent of listeriosis), and indeed other pathogens, which is superior to that of nisin A . While these laboratory-based studies demonstrate the enhanced potency of nisin V against all Gram-positive bacteria tested thus far, it is not known if this enhancement is also evident in vivo. In this study, we address this issue by comparing the efficacy of nisin A and nisin V against a lux-tagged strain of L. monocytogenes (EGDe::pPL2luxpHELP) using a murine infection model and, ultimately, demonstrate the greater efficacy of the bioengineered peptide in controlling infection.
In vitro activity of nisin A and nisin V against L. monocytogenes strains as determined by minimum inhibitory concentration assays a
Nisin A mg/L (μM)
Nisin V mg/L (μM)
Clinical (Los Angeles, California outbreak, 1985)
Although, nisin A displays relatively low cytotoxicity towards intestinal epithelial cells in vitro and shows no developmental toxicity in rat models , the cytotoxicity of nisin V would have to be investigated further before consideration for use in the clinical setting. However, the fact that nisin V lacks haemolytic activity, even at concentrations of 500 mg/L, and differs from nisin A by just one amino acid may mean that a certain amount of read-across will be permitted and a reduced panel of cytoxicity tests could be sufficient to advance commercial applications. In addition, the success with which bioengineering-based strategies have been employed to enhance its solubility , stability , diffusion  and antimicrobial activity and spectra [32, 43, 44] would suggest that other derivatives can be generated to further improve upon the functional and pharmokinetic properties of nisin. Alternatively, the use of nisin V in combination with other antimicrobials, such as lysozyme and lactoferrin , may also further enhance in vivo efficacy.
This study is the first in which the in vivo efficacy of a bioengineered nisin derivative has been assessed. The results revealed that nisin V was more effective than nisin A with respect to controlling infection with L. monocytogenes in mice. Significantly, the results validate the use of bioengineering-based strategies for peptide improvement and design and also highlight the potential of nisin V as a chemotherapeutic agent. Enhanced nisins could be especially relevant in situations where traditional antibiotic therapy has failed or where safety issues may predominate. Importantly, the safety of nisin has been well established with, for example, a 90-day oral toxicity study involving rats fed a diet containing nisin A reporting a no-observed-adverse-effect level of approximately 3000 mg/kg/day . Preliminary studies with nisin V revealed a lack of haemolytic activity, even at concentrations of 500 mg/L (D. Field unpublished results).
In conclusion, this study has determined that the enhanced potency of nisin V over nisin A is maintained in vivo against the foodborne pathogen L. monocytogenes EGDe and suggests that nisin V is a promising candidate as a therapeutic agent.
Lactococcus lactis NZ9700 and L. lactis NZ9800nisA::M21V strains were cultured in M17 broth (Oxoid) supplemented with 0.5% glucose (GM17) and GM17 agar at 30°C. Field isolates of Listeria monocytogenes and Listeria monocytogenes EGDe::pPL2luxpHELP, which harbours the luxABCDE operon of P. luminescens integrated into the chromosome at a single site , was grown in Brain Heart Infusion (BHI) broth (Oxoid) or BHI agar at 37°C.
Purification of wild type nisin A and the derivative nisin V were carried out as described previously . Briefly, overnight cultures of the wild type nisin A producing strain L. lactis NZ9700  and the nisin V producing variant L. lactis NZ9800nisA::M21V  were grown in GM17 broth at 30°C and were subsequently inoculated into two litres of purified TY broth at 1% and incubated overnight at 30°C. The culture was centrifuged at 7,000 r.p.m. for 20 minutes and the supernatant retained. The supernatant was applied to a 60 g Amberlite bead (Sigma) column, which was subsequently washed with 500 ml of 30% ethanol and the inhibitory activity eluted in 500 ml of 70% isopropanol 0.1% trifluoroacetic acid (TFA). The cell pellet was resuspended in 300 ml of 70% isopropanol 0.1% TFA and magnetically stirred for 3 hours at room temperature. The cells were removed by centrifugation at 7,000 r.p.m. for 20 minutes and the supernatant retained. The isopropanol was evaporated off using a rotary evaporator (Buchi) to a volume of 160 ml and the sample pH adjusted to approximately 4.2. The sample was applied to a 10 g (60 ml) Varian C-18 Bond Elut Column previously pre-equilibrated with HPLC water and methanol. The column was washed with 120 ml of 30% ethanol and the inhibitory activity eluted in 60 ml of 70% isopropanol 0.1% TFA. Six millilitres of the lantibiotic preparation was concentrated to 1 ml through the removal of the isopropanol by rotary evaporation and applied to a Phenomenex C12 reverse-phase (RP)-HPLC column, previously equilibrated with 25% isopropanol 0.1% TFA. The column was then developed in a gradient of 30% isopropanol 0.1% TFA to 60% isopropanol 0.1% TFA from 10 to 45 minutes at a flow rate of 2.1 ml/min. Fractions containing nisin A and nisin V peptides were collected and subjected to Mass Spectrometry with a Shimadzu Biotech MALDI-TOF Mass Spectrometer (AXIMA-CFR plus model).
Deferred antagonism assays were carried out as previously described . Briefly, 5 μl of fresh overnight cultures of L. lactis NZ9700 and L. lactis NZ9800nisA::M21V were spotted and allowed to grow on GM17 agar overnight. The colonies were subjected to 30 mins UV radiation prior to overlaying with BHI agar (0.75% w/v agar) seeded with the indicator strain L. monocytogenes EGDe::pPL2luxpHELP. The plates were then incubated at 37°C overnight and relative zone size compared.
The MIC of nisin A and nisin V against Listeria monocytogenes EGDe::pPL2luxpHELP and several field isolates of Listeria monocytogenes was carried out in triplicate as previously described . Briefly, prior to the addition of purified peptides, the 96-well microtitre plates were pre-treated with 200 μl of phosphate buffered saline (PBS) containing 1% (w/v) bovine serum albumin (BSA) and incubated at 37°C for 30 min. Wells were washed with PBS and left to dry before the addition of 100 μl BHI broth. L. monocytogenes strains were grown overnight in BHI broth at 37°C, subcultured into fresh BHI broth and grown to log phase (OD600nm of 0.5). The cultures were diluted to a concentration of 1 × 105 cfu/ml in a 0.2 ml volume. The purified peptides were resuspended in BHI broth to a stock concentration of 60 μM and adjusted to a 15 μM starting concentration. Two-fold dilutions of the peptides were made in the 96-well plates, which were subsequently inoculated with the bacterial strains and incubated at 37°C for 16 hours. The minimum inhibitory concentration (MIC) was read as the minimum peptide concentration inhibiting visible growth of the bacterial strains.
L. monocytogenes EGDe was grown overnight in BHI broth at 37°C from an isolated colony growing on a BHI agar plate containing 7.5 mg/L chloramphenicol. The overnight culture was diluted in order to facilitate its administration in a dose of 1 × 105 cfu/200 μl PBS.
All procedures involving animals were approved by the UCC Animal Experimentation Ethics Committee and carried out by a licensed individual with an ethical approval number of 2011/017. For the L. monocytogenes murine model, 15 Balb/c female mice (7 weeks old, 15 g ± 2 g in weight) were divided into three groups (A, B and C) with each group containing 5 mice. At T0 on day 1, all groups were infected with 1 × 105 viable cells of L. monocytogenes EDGe::pPL2luxpHELP in a 200 μl dose of PBS via the intraperitoneal (I.P.) route. At T0.5hrs, mice in group A were administered PBS (control), group B were treated with nisin A (58.82 mg/kg) and group C treated with nisin V (58.82 mg/kg). Both PBS and the nisin peptides were administered in 200 μl doses via the I.P. route. On day 3, the mice were anaesthetised using a mixture of aerosolised isoflurane and oxygen. Bioluminescence was monitored using an IVIS® Imaging System 100 series (Xenogen Corporation, Almeda, CA) with a 5 minute exposure time. Immediately afterward, the mice were euthanized and the livers and spleens were extracted. The organs were mechanically disrupted and serial dilutions made which were subsequently plated in 100 μl volumes on BHI agar plates containing chloramphenicol 7.5 mg/L in order to enumerate L. monocytogenes present in each organ.
IVIS imaging software was used to carry out quantification of luminescence. Bioluminescence emitted from the infection site was measured as total counts across the region of interest (designated relative light units – “RLU”) and was averaged across all groups of mice. The reduction in luminescence was quantified and represents a comparison with the luminescence from mice administered PBS control at the same time point.
CFU and RLU data was transformed to log10 prior to analysis. All comparisons were based on the mean ± standard error of the mean (SEM). Parametric data was analysed using one way analysis of variance (ANOVA) with post hoc comparison using the Student-Newman-Keuls method. Non-parametric data was analysed by the Kruskal–Wallis one way ANOVA with post hoc comparison as above. P < 0.05 was considered to be significant in all cases.
This work was carried out through a PhD Programme in Molecular Cell Biology funded by the Programme for Research in Third-Level Institutions (PRTLI) awarded to AC. Work in the authors’ laboratory is supported by the Irish Government under the National Development Plan; by the Irish Research Council for Science Engineering and Technology (IRCSET); by Enterprise Ireland; and by Science Foundation Ireland (SFI), through the Alimentary Pharmabiotic Centre (APC) at University College Cork, Ireland, which is supported by the SFI-funded Centre for Science, Engineering and Technology (SFI-CSET) and provided PDC, CH and RPR with SFI Principal Investigator funding.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.